sars-cov-2 adjuvanted recombinant protein vaccine (bivalent)
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 26, 2021 (NCT04904549)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Spike glycoproteinImmunity, active
Spike glycoprotein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04904549 | Phase 3 | May 26, 2021 | GlaxoSmithKline, Sanofi, Sanofi-Aventis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2021 |
| Sanofi | For profit | 1 | 0 | 1 | 2021 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1